$Chimerix (CMRX.US)$PR 12/9 after hours To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End. Ran 100%+ but this is after hour news with conference call tomorrow at 8:30AM ET. May continue. $Cumberland Pharmaceuticals (CPIX.US)$PR 12/9 after hours: FDA approval of sNDA Acetadote, a simplified IV medication for acetaminophen poisioning. Low float. 0 shares LTB $DatChat (DATS.US)$PR 12/9 ...
$Chimerix (CMRX.US)$Chimerix To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End Benzinga· 1 min ago Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET
$Chimerix (CMRX.US)$ Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End Monday, 9th December at 4:01 pm Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET
$Cumberland Pharmaceuticals (CPIX.US)$ PR 12/9 after hours: FDA approval of sNDA Acetadote, a simplified IV medication for acetaminophen poisioning. Low float. 0 shares LTB
$DatChat (DATS.US)$ PR 12/9 ...
On Watch for tomorrow, likely will be a target for shorts though, we'll see.
📊⚡️📊
Benzinga· 1 min ago
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma
Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA
Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
Monday, 9th December at 4:01 pm
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma
Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA
Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET
No comment yet